Dyson

Last updated January 31, 2026

Innovation Areas

1,861

Inventors

Collaborations

Multispecific antibody structural scaffolds: DysonRecent Research Landscape

Inefficient tumor targeting and off-target toxicity increase clinical failure risks, which are mitigated through precise trispecific molecular scaffolding. Engineering these specific binding domains ensures simultaneous engagement of multiple antigens to enhance therapeutic potency.

What technical problems is Dyson addressing in Multispecific antibody structural scaffolds?

Insufficient target binding specificity

(3)evidences

Low binding avidity and poor proximity between effector and multiple tumor-associated antigens. Enhancing multi-antigen recruitment improves therapeutic specificity and overcomes immune escape mechanisms.